Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016

Details for Mechanism ID: 16397
Country/Region: Tanzania
Year: 2015
Main Partner: Deloitte Consulting Limited
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USAID
Total Funding: $19,771,720 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $5,479,616
Care: TB/HIV (HVTB) $420,737
Care: Pediatric Care and Support (PDCS) $461,331
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Testing: HIV Testing and Counseling (HVCT) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $4,214,537
Treatment: Adult Treatment (HTXS) $8,734,168
Treatment: Pediatric Treatment (PDTX) $461,331
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 150,940
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 36,568
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 32,827
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 58,143
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2016 5
LAB_CAP By clinical laboratories 2016 165
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 165
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 1,723
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 4,938
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 1,650
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 4,065
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 782
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 1,914
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 868
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 2,151
PMTCT_ARV Sum of New and Current disaggregates 2016 1,650
PMTCT_ARV Sum of New and Current disaggregates 2016 4,065
PMTCT_CTX Number of infants born to HIV-infected women who were started on cotrimoxizole (CTX) prophylaxis within 2 months of birth within the reporting period 2016 3,254
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 2,569
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 1,111
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 3,680
PMTCT_EID Sum of Infant Age disaggregates 2016 3,680
PMTCT_STAT By: Known positives at entry 2016 517
PMTCT_STAT By: Known positives at entry 2016 1,481
PMTCT_STAT By: Number of new positives identified 2016 1,206
PMTCT_STAT By: Number of new positives identified 2016 3,457
PMTCT_STAT Number of new ANC and L&D clients 2016 35,092
PMTCT_STAT Number of new ANC and L&D clients 2016 62,771
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 33,344
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 59,624
PMTCT_STAT Sum of Positives Status disaggregates 2016 1,723
PMTCT_STAT Sum of Positives Status disaggregates 2016 4,938
TB_IPT The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period 2016 8,157
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 150,940
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 143,731
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 140,135
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 34,908
Cross Cutting Budget Categories and Known Amounts Total: $2,090,000
Human Resources for Health $1,900,000
Gender: Gender Based Violence (GBV) $40,000
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $150,000
Equity in HIV prevention, care, treatment and support
Implementation